Nanomix (Nanomix) Days Payable : 0.00 (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Nanomix Days Payable?

Nanomix's average Accounts Payable for the three months ended in Dec. 2022 was $1.16 Mil. Nanomix's Cost of Goods Sold for the three months ended in Dec. 2022 was $0.00 Mil.

The historical rank and industry rank for Nanomix's Days Payable or its related term are showing as below:

NNMX's Days Payable is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 72.55
* Ranked among companies with meaningful Days Payable only.

Nanomix's Days Payable stayed the same from Dec. 2021 (0.00) to Dec. 2022 (0.00). stayed the same

Nanomix Days Payable Historical Data

The historical data trend for Nanomix's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanomix Days Payable Chart

Nanomix Annual Data

Trend

Dec20

Dec21

Dec22

Days Payable

Nanomix Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Days Payable	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Nanomix's Days Payable

For the Medical Devices subindustry, Nanomix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanomix's Days Payable Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanomix's Days Payable distribution charts can be found below:

* The bar in red indicates where Nanomix's Days Payable falls into.

Nanomix Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Nanomix's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (0.763	+	1.295)	/	2 )	/	0	*	365
=	1.029					/	0	*	365
=	N/A

Nanomix's Days Payable for the quarter that ended in Dec. 2022 is calculated as:

	Days Payable (Q: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2022 )	+	Accounts Payable (Q: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2022 )	*	Days in Period
=	( (1.033	+	1.295)	/	2 )	/	0	*	365 / 4
=	1.164					/	0	*	365 / 4
=	N/A

Nanomix Days Payable Related Terms

Thank you for viewing the detailed overview of Nanomix's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanomix (Nanomix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

2121 Williams Street, San Leandro, CA, USA, 94577

Website

https://www.nanomixdx.com

Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.

Executives

Chris Hetterly	officer: Chief Financial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener	director, 10 percent owner	ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger	director, officer: CEO	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney	officer: Chief Operating Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky	officer: Chief Commercial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson	director, officer: CEO and President	BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman	director	1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham	officer: Chief Operating Officer	C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch	director, officer: CEO
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng	director	ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia	officer: Chief Financial Officer	PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin	director	C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome	officer: Chief Operating Officer (3)	178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz	director	33 KACHAL STREET, LEHAVIM L3 85338